< Back to previous page
Researcher
Christophe Pannecouque
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Jul 2002 → Today
Projects
1 - 3 of 3
- An automated platform for multiparameter data collection on live pathogens of higher or unknown biosafety risk.From26 Jun 2014 → 31 Dec 2018Funding: Hercules - Large scale research infrastructure
- Mechanistic study on virus entry and replication. A fundamental approach to the development of new and specific antiviral chemotherapeutics.From1 Jan 2010 → 31 Dec 2014Funding: BOF - Concerted Research Project from 1994
- Identification of biomarkers and new therapeutic targets in HTLV-1-associated pathologies.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project
Publications
41 - 50 of 399
- Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors(2022)
Authors: Christophe Pannecouque, Erik De Clercq
- Design, Synthesis and Structure-Activity Relationships of Phenylalanine-Containing Peptidomimetics as Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction(2022)
Authors: Erik De Clercq, Christophe Pannecouque
- Structure-Based design of [(2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives as nonnucleoside HIV-1 reverse transcriptase Inhibitors: From HEPTs to Sulfinyl-substituted HEPTs(2022)
Authors: Christophe Pannecouque, Erik De Clercq
- Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features(2022)
Authors: Erik De Clercq, Christophe Pannecouque
- Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase(2022)
Authors: Christophe Pannecouque, Erik De Clercq
- Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine(2022)
Authors: Abhi Singh, Dominique Schols, Piet Herdewyn, Christophe Pannecouque, Kalyan Das
- Structure-Based Discovery of Novel NH2 -Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH2-Naphthyl-Diarylpyrimidine to NH2 -Biphenyl-Diarylpyrimidine(2022)
Authors: Christophe Pannecouque, Erik De Clercq
Pages: 8478 - 8492 - Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors(2022)
Authors: Christophe Pannecouque, Erik De Clercq
Pages: 3729 - 3757 - Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK(2022)
Authors: Christophe Pannecouque, Erik De Clercq
Pages: 2122 - 2138 - Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C(2022)
Authors: Erik De Clercq, Christophe Pannecouque
Pages: 2458 - 2470
Patents
1 - 7 of 7
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral activity of novel bicyclic heterocycles (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION (Inventor)